Gameto lands $33 million to advance women’s reproductive health

Female reproductive longevity biotech is targeting fertility, ovarian disease, menopause and beyond.

Women’s health biotech Gameto has successfully closed a $33 million Series B financing round to advance its reproductive health programs. While the new funding will primarily support the clinical development of Fertilo, the company’s investigational fertility solution that matures eggs outside the body, Gameto’s longer-term goals are more longevity-focused.

Fertility rates in the US have reached their lowest in a century and, as people live longer, many women can now expect to spend more of their lives in menopause than fertile due to the premature aging of the female reproductive system. Gameto is on a mission to solve menopause, and aims to synchronize the pace of ovarian aging to the rate of aging in other organs.

“The pathways that drive ovarian aging are similar to those that drive systemic aging, but they just occur faster in the ovary,” Dr Dina Radenkovic, CEO of Gameto told us previously.

Gameto co-founder Dina Radenkovic at work in the lab.

The oversubscribed funding round, which brings Gameto’s total funding to $73 million, was led by Two Sigma Ventures and RA Capital, with participation from existing investors, including Insight Partners, Future Ventures, and BOLD Capital Partners. Individual investors, including Olivia Walton, Stacey Bendet Eisner, and Chelsea Hirschhorn, also participated. The company secured a $20 million Series A round in 2022.

“These funds will support our late-stage clinical development in the US, post-market surveillance outside the US and the creation of a commercial operations function,” said Radenkovic. “I believe that each small step we take in investing in women’s health can lead to a giant leap in medical breakthroughs and innovation.”

Highlighting the reproductive challenges facing women today, RA Capital Management’s Peter Kolchinsky said, “To contemplate the importance of easing that burden, of expanding the freedom of many to have children when they are ready, it’s hard to overestimate the potential impact of such an advance on humanity, for all of our society, for the rest of time.”

READ MORE: Our exclusive interview with Gameto founder Dina Radenkovic

Martin Varsavsky, Chairman of Gameto, is speaking on female reproductive longevity at Founders Longevity Forum – FIND OUT MORE.

Photographs courtesy of Gameto